Heart Failure

4. Abnormal findings — the necessity chain

Finding → severity → comparison → risk → intervention → notification (provider + representative) → orders → response → reassessment.

*Model abnormal 1*
Heart-failure decompensation: a 4-lb weight gain over 48 hours, new 3+ pretibial edema, bibasilar crackles, jugular venous distension, a new S3, and mild orthopnea — early decompensation. Applied the parameter-based diuretic order; SBAR to the provider at 14:10, an order to increase furosemide per the protocol dose and obtain a BMP/BNP within 48 hours received; the dose administered (witnessed) at 14:25; responsible party notified at 14:30. The resident reported relief after voiding; reassessment scheduled next shift; supports Section N. Skilled titration and volume assessment required daily at SNF level.

Model abnormal 1

Heart-failure decompensation: a 4-lb weight gain over 48 hours, new 3+ pretibial edema, bibasilar crackles, jugular venous distension, a new S3, and mild orthopnea — early decompensation. Applied the parameter-based diuretic order; SBAR to the provider at 14:10, an order to increase furosemide per the protocol dose and obtain a BMP/BNP within 48 hours received; the dose administered (witnessed) at 14:25; responsible party notified at 14:30. The resident reported relief after voiding; reassessment scheduled next shift; supports Section N. Skilled titration and volume assessment required daily at SNF level.

*Model abnormal 2*
GDMT-tolerance problem: symptomatic hypotension (BP 92/54 with lightheadedness) after the last beta-blocker/ARNI dose, or a rising potassium/creatinine on labs — the next dose held per the parameters, the provider notified with the values, orders received (dose adjustment, repeat labs), and the resident monitored. Will reassess vitals/labs; supports the Section N update. Skilled recognition and management of the GDMT tolerance required.

Model abnormal 2

GDMT-tolerance problem: symptomatic hypotension (BP 92/54 with lightheadedness) after the last beta-blocker/ARNI dose, or a rising potassium/creatinine on labs — the next dose held per the parameters, the provider notified with the values, orders received (dose adjustment, repeat labs), and the resident monitored. Will reassess vitals/labs; supports the Section N update. Skilled recognition and management of the GDMT tolerance required.

1. Purpose and clinical relevance

4. Abnormal findings — the necessity chain